The phase IIIb PONENTE trial* aims to assess if adults with severe eosinophilic asthma who are treated with benralizumab can safely reduce their doses of oral corticosteroid (OCS) therapy, while still maintaining asthma control.
The anti-interleukin-5 receptor alpha monoclonal antibody benralizumab significantly reduced the rates of severe exacerbations (SevEx) and asthma worsening episodes (AWE) in patients with severe asthma, leading to a reduction in the risk of overall CompEx* events, according to a post hoc analysis of the phase III SIROCCO** and CALIMA*** trials presented at ATS 2019.
Using budesonide/formoterol as needed was as effective as budesonide maintenance therapy in preventing exacerbations but with a lower exposure to ICS among patients with mild asthma, including adolescent patients and regardless of prior treatment used, according to two subgroup analyses of the SYGMA* 1 and 2 studies presented at the ATS 2019 Congress.
Influenza vaccination effectively reduced the risk of influenza-related hospitalizations in patients with chronic obstructive pulmonary disease (COPD) compared with those who were not vaccinated, according to a study presented at ATS 2019.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.